Vetter accelerates market introduction of the new V-OVS® next injection closure system

V-OVS® mounted on a syringe. © Vetter Pharma International GmbH

– New studies demonstrate high user-friendliness and performance
– Design finalized and preparations for serial production initiated
– New features set a new standard

Vetter, a partner of global pharmaceutical and biotech companies for the manufacturing of life-improving medications, is working intensively on the market launch of V-OVS® next, the next generation of its successful syringe closure system V-OVS®, planned for 2027. After a study successfully completed in early 2025, Vetter has now achieved further milestones in ongoing development: a second human factors study and an important functionality study confirm the positive results for the new closure system. Additionally, the design of the new flagship product has been finalized and preparations for serial production have been set in motion.

In-depth insights from multiple studies

While the first human factors study focused on the product and user, the second study also included a usage-related risk analysis. It confirms the intuitive, safe, and effective handling of V-OVS® next. The design was also rated as user-friendly by study participants. Among other findings, the probability of misuse is reduced, according to one of the results. Furthermore, Vetter tested the structural performance of the new system during manufacturing and handling.

“Our goal was to combine safety, user-friendliness, and design in such a way that users receive real added value,” says Dr. Claus Feussner, Senior Vice President Development Service at Vetter. “The positive study results confirm that we can achieve this goal with V-OVS® next.”

Early involvement of partners and suppliers

The multi-stage development process at Vetter also includes actively involving partners and suppliers. In the next step, the company provides its syringe glass suppliers with samples. This gives suppliers the opportunity to test the implementation in their production across a range of different syringe formats.

“The first biopharma customers already gave us positive feedback at Pharmapack 2025. Now we look forward to involving some glass suppliers and hearing their opinions on our further developed closure system,” says Lars Hahn, Senior Vice President of Global Sales Organization at Vetter. “We have already had successful discussions with several partners along the value chain. Their consistently encouraging reactions reinforce our path toward market launch.”

More intuitive handling, innovative functionality, high-quality design

The new syringe closure system, developed based on extensive market studies and customer feedback, combines intuitive handling, innovative functionality, and high-quality design. It is suitable for a variety of syringe formats. In particular, the new system aims to further improve, secure, and simplify applications in ophthalmology, aesthetic injections, reconstitution solutions, and biologics.

Even after the market launch of the new V-OVS® next, Vetter will continue to offer the proven V-OVS® closure system. With the introduction of the next generation, Vetter expands its solution portfolio for syringe-based products. Additionally, V-OVS® and V-OVS® next use the same contact materials, making an upgrade to the new system a lifecycle measure for existing medicines or a differentiating feature for new medicines easier.